|
시장보고서
상품코드
1935493
자궁경부암 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)Global Cervical Cancer Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034 |
||||||
자궁경부암 치료 시장 규모는 2025년 96억 4,000만 달러에서 2026년부터 2034년까지 CAGR 6.02%로 성장하여 2034년에는 163억 2,000만 달러에 달할 것으로 예측됩니다.
자궁경부암 치료 시장은 자궁경부암 발생률 증가와 예방 및 치료 옵션에 대한 인식이 높아짐에 따라 큰 폭의 성장이 예상됩니다. 주로 인유두종바이러스(HPV) 감염에 의해 발생하는 자궁경부암은 전 세계 여성들에게 심각한 건강 위험으로 대두되고 있습니다. 의료 서비스 제공자와 조직이 조기 발견과 효과적인 치료를 우선시함에 따라 수술, 방사선 치료, 화학요법 등 자궁경부암 치료에 대한 수요가 증가할 것으로 예상되며, 자궁경부암 치료 시장은 견조한 성장세를 보일 것으로 전망됩니다.
또한, 자궁경부암 치료 기술의 발전은 시장 내 혁신을 촉진하고 있습니다. 표적 치료제와 면역치료제의 개발은 치료의 지형을 바꾸고 있으며, 진행성 또는 재발성 자궁경부암 환자들에게 새로운 치료 옵션을 제공하고 있습니다. 이러한 혁신적인 접근 방식은 치료 효과를 향상시킬 뿐만 아니라 부작용을 최소화하고 환자의 전반적인 삶의 질(QOL)을 향상시킵니다. 새로운 치료법과 병용요법에 대한 연구가 계속되는 가운데, 환자 예후가 개선될 것으로 예상됨에 따라 자궁경부암 치료 시장은 더욱 확대될 가능성이 높습니다.
또한, 예방의료와 백신 접종에 대한 관심이 높아지면서 자궁경부암 치료의 상황을 형성하고 있습니다. HPV 백신의 도입으로 접종 집단의 자궁경부암 발생률이 크게 감소하여 예방책의 중요성이 부각되었습니다. 백신 접종과 정기 검진의 이점에 대한 인식이 높아짐에 따라 자궁경부암 치료에 대한 수요는 예방과 효과적인 질병 관리에 초점을 맞춘 형태로 진화할 것으로 예상됩니다. 자궁경부암 치료 시장이 계속 성장하고 있는 가운데, 혁신적인 치료법, 예방 전략, 환자 치료 개선 노력은 자궁경부암 치료 시장의 미래 궤도를 형성하는 데 있어 매우 중요한 역할을 할 것입니다.
목차
제1장 소개
제2장 주요 요약
제3장 시장 변수, 동향, 프레임워크
제4장 세계의 자궁경부암 치료 시장 : 유형별
제5장 세계의 자궁경부암 치료 시장 : 치료법별
제6장 세계의 자궁경부암 치료 시장 : 최종사용별
제7장 세계의 자궁경부암 치료 시장 : 지역별
제8장 경쟁 구도
제9장 기업 개요
KSM 26.03.11The Cervical Cancer Treatment Market size is expected to reach USD 16.32 Billion in 2034 from USD 9.64 Billion (2025) growing at a CAGR of 6.02% during 2026-2034.
The cervical cancer treatment market is poised for significant growth, driven by the increasing incidence of cervical cancer and the rising awareness of preventive measures and treatment options. Cervical cancer, primarily caused by human papillomavirus (HPV) infection, poses a significant health risk to women worldwide. As healthcare providers and organizations prioritize early detection and effective treatment, the demand for cervical cancer therapies, including surgery, radiation therapy, and chemotherapy, is expected to rise, positioning this market for robust expansion.
Moreover, advancements in cervical cancer treatment technologies are driving innovation within the market. The development of targeted therapies and immunotherapies is revolutionizing the treatment landscape, offering new options for patients with advanced or recurrent cervical cancer. These innovative approaches not only improve treatment efficacy but also minimize side effects, enhancing the overall quality of life for patients. As research continues to explore new therapeutic modalities and combination treatments, the cervical cancer treatment market is likely to expand further, driven by the promise of improved patient outcomes.
Additionally, the growing emphasis on preventive care and vaccination is shaping the cervical cancer treatment landscape. The introduction of HPV vaccines has significantly reduced the incidence of cervical cancer in vaccinated populations, highlighting the importance of preventive measures. As awareness of the benefits of vaccination and regular screenings increases, the demand for cervical cancer treatments is expected to evolve, focusing on both prevention and effective management of the disease. As the cervical cancer treatment market continues to grow, the combination of innovative therapies, preventive strategies, and a commitment to improving patient care will play a crucial role in shaping its future trajectory.
Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:
Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.
Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.
Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.
Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.
Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.
Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.
Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.
MARKET SEGMENTATION
By Type
- Squamous Cell Carcinoma
- Adenocarcinoma
- Adenosquamous Carcinoma
- Others
By Treatment
- Radiation Therapy
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Others
By End-use
- Hospitals & Clinics
- Ambulatory Surgery Centers
- Others
COMPANIES PROFILED
- Merck Co Inc, BristolMyers Squibb Company, F HoffmannLa Roche Ltd, Pfizer Inc, Eli Lilly and Company, Novartis AG, AstraZeneca, GSK plc, AbbVie Inc, Johnson Johnson Services Inc
We can customise the report as per your requriements
TABLE OF CONTENTS
Chapter 1. PREFACE
- 1.1. Market Segmentation & Scope
- 1.2. Market Definition
- 1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources
Chapter 2. EXECUTIVE SUMMARY
- 2.1. Market Snapshot
- 2.2. Segmental Outlook
- 2.3. Competitive Outlook
Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK
- 3.1. Market Lineage Outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Value Chain Analysis
- 3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
- 3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
- 3.6. Porter's Five Forces Analysis
- 3.7. PESTLE Analysis
Chapter 4. GLOBAL CERVICAL CANCER TREATMENT MARKET: BY TYPE 2022-2034 (USD MN)
- 4.1. Market Analysis, Insights and Forecast Type
- 4.2. Squamous Cell Carcinoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.3. Adenocarcinoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.4. Adenosquamous Carcinoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 5. GLOBAL CERVICAL CANCER TREATMENT MARKET: BY TREATMENT 2022-2034 (USD MN)
- 5.1. Market Analysis, Insights and Forecast Treatment
- 5.2. Radiation Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.3. Chemotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.4. Targeted Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.5. Immunotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 6. GLOBAL CERVICAL CANCER TREATMENT MARKET: BY END-USE 2022-2034 (USD MN)
- 6.1. Market Analysis, Insights and Forecast End-use
- 6.2. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.3. Ambulatory Surgery Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 7. GLOBAL CERVICAL CANCER TREATMENT MARKET: BY REGION 2022-2034(USD MN)
- 7.1. Regional Outlook
- 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.2.1 By Type
- 7.2.2 By Treatment
- 7.2.3 By End-use
- 7.2.4 United States
- 7.2.5 Canada
- 7.2.6 Mexico
- 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.3.1 By Type
- 7.3.2 By Treatment
- 7.3.3 By End-use
- 7.3.4 United Kingdom
- 7.3.5 France
- 7.3.6 Germany
- 7.3.7 Italy
- 7.3.8 Russia
- 7.3.9 Rest Of Europe
- 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.4.1 By Type
- 7.4.2 By Treatment
- 7.4.3 By End-use
- 7.4.4 India
- 7.4.5 Japan
- 7.4.6 South Korea
- 7.4.7 Australia
- 7.4.8 South East Asia
- 7.4.9 Rest Of Asia Pacific
- 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.5.1 By Type
- 7.5.2 By Treatment
- 7.5.3 By End-use
- 7.5.4 Brazil
- 7.5.5 Argentina
- 7.5.6 Peru
- 7.5.7 Chile
- 7.5.8 South East Asia
- 7.5.9 Rest of Latin America
- 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.6.1 By Type
- 7.6.2 By Treatment
- 7.6.3 By End-use
- 7.6.4 Saudi Arabia
- 7.6.5 UAE
- 7.6.6 Israel
- 7.6.7 South Africa
- 7.6.8 Rest of the Middle East And Africa
Chapter 8. COMPETITIVE LANDSCAPE
- 8.1. Recent Developments
- 8.2. Company Categorization
- 8.3. Supply Chain & Channel Partners (based on availability)
- 8.4. Market Share & Positioning Analysis (based on availability)
- 8.5. Vendor Landscape (based on availability)
- 8.6. Strategy Mapping
Chapter 9. COMPANY PROFILES OF GLOBAL CERVICAL CANCER TREATMENT INDUSTRY
- 9.1. Top Companies Market Share Analysis
- 9.2. Company Profiles
- 9.2.1 Merck & Co. Inc
- 9.2.2 Bristol-Myers Squibb Company
- 9.2.3 F. Hoffmann-La Roche Ltd
- 9.2.4 Pfizer Inc
- 9.2.5 Eli Lilly And Company
- 9.2.6 Novartis AG
- 9.2.7 AstraZeneca
- 9.2.8 GSK Plc
- 9.2.9 AbbVie Inc
- 9.2.10 Johnson & Johnson Services Inc
